Nxstage Medical, Inc. (NASDAQ:NXTM) Q1 2019 Earnings Conference Call Transcript
May 02, 2019 • 04:30 pm ET
We would like to welcome all of you to the (inaudible) Earnings Call for the First Quarter 2019. We appreciate you joining today. Also you might be already very tired from all the earnings releases today.
Before we start, I would like to use the opportunity for some short marketing. We will to do a conference call on home dialysis to explain the strategic logic and medical backgrounds. It will not be about how to model the financials. This will take place on the 20th of May at 2:00 PM CET and on 27th of June, we do offer a site visit to our production site in St. Wendel in Germany. Details for both events are posted on our website.
Now, it is my pleasure to start out the call by mentioning our cautionary language that is in our Safe Harbor statement as that as in our presentation and in all the materials that we have distributed the earlier today. For further details concerning risks and uncertainties, please refer to these documents as well as to our SEC filing.
As always, I'd like to limit the number of questions again to two in order to give everyone the chance to ask a question. I hope this works for everyone. I assume you might be tired anyhow on this eventful day.
With us today is of course Rice Powell, our CEO and Chairman of the Management Board. Rice will give you some more color around the strategy and business development goes with some of the major topics of the quarter, of course, also with us is Mike Brosnan, our Chief Financial Officer, who will give you an update on the finances and the outlook.
I will now hand over to Rice, the floor is yours.
Thank you, Dominik. Good morning, good afternoon to everyone depending on where you are. We're great -- it's great to have you with us today and we appreciate your interest in the first quarter of 2019.
Turning to Slide 4, and looking at some key parameters of the service business. You can see our clinic growth in the quarter, patient growth and treatment growth. I would also say looking at our statement quality remains on a consistently high level.
Why don't we turn to Slide 5 and you can see that in print that our quality outcomes do remain on a high level, our quality indicators do look quite well. I would like to make one point you probably saw an announcement from us a couple of weeks ago that we've created the global medical office. Wanted to make sure you understand that we believe we are at the right time in our company's history to really take more of a global approach to the medicine in driving the clinical outcomes across the regions as we continue to see product businesses turn into service businesses, and the opportunities to try to work closer with payers.
I'm happy to say that Frank Maddux has been appointed the Global